Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01909492 · ClinicalTrials.gov registry record
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
A clinical trial, sponsored by Providence Health & Services.
- Completed
- Registry status
- 30
- Enrollment target
NCT01909492: Completed study, sponsored by Providence Health & Services.
NCT01909492 is a clinical trial that has completed, run by Providence Health & Services. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01909492 has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
Primary Outcome
There is no information available on what serum and CSF levels of RLX are observed in patients with active versus stable relapsing MS, how these values compare to that found in human volunteers without MS or other inflammatory diseases, and whether RLX functions normally in subjects with active or stable MS. RLX2 concentrations were expressed as picomoles per milliliter (pmol/mL) of serum or CSF.
Interventions
- PROCEDURE Lumbar Puncture
- PROCEDURE Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-09-20 |
| Est. Completion | 2023-10-05 |
What the finished NCT01909492 record still lists
NCT01909492 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Lumbar Puncture is the first listed.
NCT01909492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01909492 about?
NCT01909492 is a clinical study titled "Measurement of Relaxin Peptide in Multiple Sclerosis (MS)". This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
What is the current status of trial NCT01909492?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-09-20. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT01909492?
The interventions under investigation include: Lumbar Puncture (PROCEDURE), Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT01909492?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI